Adaptin Bio (APTN) Liabilities and Shareholders Equity (2022 - 2026)

Adaptin Bio has disclosed Liabilities and Shareholders Equity across 5 years of filings, most recently posting $981452.0 for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 40.97% year-over-year to $981452.0; the TTM figure through Jun 2026 stood at $3.3 million (down 30.91% YoY), while the FY2025 annual figure was $619159.0, up 158.61% from the prior year.
• Liabilities and Shareholders Equity came in at $981452.0 for Q2 2026 at Adaptin Bio, up from $706117.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.9 million in Q1 2025 to a low of $322.0 in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $618810.8, with a median of $239415.0 recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity soared 750953.68% in 2025 and sank 75.26% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $500.0 in 2022, then decreased by 24.0% to $380.0 in 2023, then surged by 62903.95% to $239415.0 in 2024, then soared by 158.61% to $619159.0 in 2025, then surged by 58.51% to $981452.0 in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $981452.0 in Q2 2026, $706117.0 in Q1 2026, and $619159.0 in Q4 2025.